Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue |
| |
Authors: | Ming Hui Chen |
| |
Institution: | (1) Department of Cardiology, Children’s Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA |
| |
Abstract: | Increasing use of targeted anticancer agents that inhibit tyrosine kinase signaling (monoclonal antibodies or tyrosine kinase
inhibitors) has dramatically improved the survival of patients with malignancies. However, cardiotoxicity, including heart
failure, left ventricular dysfunction, hypertension, myocardial infarction, and thromboembolism, has occurred. Importantly,
these cardiotoxicities are at least partially reversible and responsive to medical management. Early recognition of cardiovascular
side effects is vital to allow long-term, continuous therapy with these life-prolonging agents. This article reviews potential
cardiovascular side effects of frequently used inhibitors of tyrosine kinase activity (eg, trastuzumab, sunitinib) and discusses
the diagnosis and management of cardiotoxicity associated with targeted therapy. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|